FOG-001 in Locally Advanced or Metastatic Solid Tumors | MicrobiomeTrials← Back to trialsNCT05919264
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2023-05-23Est. Completion: 2027-04-01
Enrollment target: 619 participants Locations- Mayo Clinic, Phoenix, Arizona, United States
- Honor Health, Scottsdale, Arizona, United States
- Arizona Cancer Center at University of Arizona, Tucson, Arizona, United States
- University of California, Los Angeles (UCLA), Los Angeles, California, United States
- Stanford Cancer Institute, Stanford University, Palo Alto, California, United States
- University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
- Sarcoma Oncology Center, Santa Monica, California, United States
- University of Colorado, Aurora, Colorado, United States
- Yale University School of Medicine, New Haven, Connecticut, United States
- Johns Hopkins University, Sibley Memorial Hospital, Washington D.C., District of Columbia, United States
- Mayo Clinic, Jacksonville, Florida, United States
- Florida Cancer Specialists, Lake Mary, Florida, United States
- Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
Other microbiome trials you might be interested in
Very Rare TumorsVery Rare CancersOther Solid TumorsSolid TumorPediatric Rare Tumors
Background:
All childhood cancers are rare, but some are called very rare. Very rare cancers are diagnosed in 2 or fewe…
Bethesda, United StatesEst. completion Apr 1, 2035
Muscle Invasive Bladder Urothelial CarcinomaMuscle Invasive Renal Pelvis Urothelial CarcinomaMuscle Invasive Ureter Urothelial Carcinoma
Dana Farber Cancer Institute, Boston, Massachusetts, United StatesM Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United StatesMayo Clinic, Rochester, Minnesota, United StatesWashington University School of Medicine, St Louis, Missouri, United StatesMemorial Sloan Kettering Cancer Center, New York, New York, United StatesDuke University, Durham, North Carolina, United StatesUniversity Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, Ohio, United StatesCleveland Clinic, Cleveland, Ohio, United StatesOregon Health and Science University, Portland, Oregon, United StatesUniversity of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, United StatesUniversity of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, Pennsylvania, United StatesSarah Cannon Research Institute, Nashville, Tennessee, United StatesVanderbilt Ingram Cancer Center, Nashville, Tennessee, United StatesThe University of Texas MD Anderson Cancer Center, Houston, Texas, United StatesSouth Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United StatesUniversity of Virginia, Charlottesville, Virginia, United StatesUniversity of Wisconsin, Carbone Cancer Center, Madison, Wisconsin, United StatesIntegrated Clinical Oncology Network (ICON), South Brisbane, Queensland, AustraliaPeter MacCallum Cancer Centre, Melbourne, Victoria, AustraliaMuscle Invasive Urethral Urothelial Carcinoma
Stage II Bladder Urothelial Carcinoma AJCC v6 and v7
Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
Stage IV Bladder Urothelial Carcinoma AJCC v7
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or uret…
Phoenix, United StatesEst. completion Sep 2, 2030
B-cell Acute Lymphoblastic LeukemiaDiffuse Large B-cell LymphomaBurkitt LymphomaNeuroblastomaEwing Sarcoma
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab…
Los Angeles, United StatesEst. completion Mar 31, 2029